Verrica Pharmaceuticals stock drops following another setback for its lead drug candidate

The Food and Drug Administration has once again delayed a decision on a West Chester pharmaceutical company's lead new drug application, but the issue has nothing to do with the experimental drug's effectiveness. Instead, Verrica Pharmaceuticals said Tuesday, the federal agency identified deficiencies at a facility of a contract manufacturing organization that makes Verrica's experimental drug known as VP-102. The alleged deficiencies, the company said, are not specifically related to the manufacturing…
Source: bizjournals.com Health Care:Pharmaceuticals headlines - Category: Pharmaceuticals Authors: Source Type: news